Is Minerva Surgical, Inc. overvalued or undervalued?

As of 11 May 2022, the valuation grade for Minerva Surgical, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued given its current metrics, particularly with a P/E ratio of 0.00, an EV to EBIT of -0.85, and an EV to EBITDA of -1.14, which suggest a lack of profitability and operational efficiency.
In comparison to its peers, Silk Road Medical, Inc. has a P/E ratio of -19.76 and an EV to EBITDA of -18.12, while Cytek Biosciences, Inc. shows a P/E of -33.33 and an EV to EBITDA of -15.41, both indicating that Minerva Surgical is underperforming relative to its industry. Additionally, the company's one-year return of -99.17% starkly contrasts with the S&P 500's return of 17.14%, reinforcing the notion that Minerva Surgical is struggling significantly in the market.